Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Cancer supportive care products can be defined as products or drugs that are mainly used for treatment of adverse effects associated with cancer therapy as well as for treatment of symptoms and signs of cancer such nausea, vomiting, hair loss, low blood counts, and others.
The global cancer supportive care products market is estimated to account for US$ 40,884.0 Mn in terms of value by the end of 2027.
Global Cancer Supportive Care Products Market: Drivers
High prevalence of cancer is expected to propel growth of the global cancer supportive care products market over the forecast period. For instance, according to the American Cancer Society, in 2019, there will be an estimated 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the U.S.
Moreover, increasing funding in cancer R&D is also expected to aid in growth of the global cancer supportive care products market. For instance, according to the National Cancer Research Institute (NCRI), cancer research funding by NCRI partners reached around US$ 750 million in 2018/19.
North America held dominant position in the global cancer supportive care products market in 2019, accounting for 43.6% share in terms of value, followed by Europe and Asia Pacific, respectively.
Figure 1: Global Cancer Supportive Care Products Market Share (%) Value, By Region, 2019
Global Cancer Supportive Care Products Market: Restraints
Loss of brands exclusivity of various generic drugs is expected to hinder growth of the global cancer supportive care products market.
Moreover, entry of biosimilars is also expected to limit growth of the global cancer supportive care products market. Patents for certain major drugs used in cancer supportive care products have expired or are expected to expire in the near future. This is projected to open the gateway for biosimilars for anti-cancer therapy, which would lead to drastic decrease in prices of patent-expired drugs.
Cancer Supportive Care Products Market Report Coverage
||Market Size in 2019:
||US$ 27,244.1 Mn
|Historical Data for:
||2016 to 2019
||2020 to 2027
|Forecast Period 2020 to 2027 CAGR:
||2027 Value Projection:
||US$ 40,884.0 Mn
- North America: U.S., Canada
- Latin America: Brazil, Argentina, Mexico, Rest of Latin America
- Europe: Germany, U.K., France, Spain, Italy, Russia, Rest of Europe
- Asia Pacific: China, Japan, India, Australia, South Korea, ASEAN, Rest of Asia Pacific
- Middle East: GCC Countries, Israel, Rest of Middle East
- Africa: North Africa, Central Africa, South Africa
- By Drug Class: Nonsteroidal Anti- Inflammatory Drugs, Anti-Infective, Anti-Emetics, Monoclonal Antibodies, Erythropoietin Stimulating Agents, Opioid Analgesics, Bisphosphonates, Granulocyte Colony Stimulating Factor.
- By Indication: Lung Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Bladder Cancer, Leukemia, Ovary Cancer, Melanoma Cancer, Others.
- By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Compounding Pharmacies.
Amgen Inc., Johnson & Johnson Private Ltd., Merck, Novartis AG, Baxter International, Hoffmann-La Roche Ltd., Fagron, Teva Pharmaceutical Industries Ltd., G1 Therapeutics Inc., APR Applied Pharma Research s.a., Acacia Pharma, EMD Serono, and Kyowa Hakko Kirin Co., Ltd.
- Increasing prevalence of cancer
- Approval and launch of new products
|Restraints & Challenges:
- Loss of brands exclusivity of various generic drugs
Global Cancer Supportive Care Products Market: Opportunities
Increasing investment in the pharmaceutical sector is expected to offer lucrative growth opportunities for players in the global cancer supportive care products market. For instance, according to The European Federation of Pharmaceutical Industries and Associations’ Key Data 2019, the pharmaceutical sector in Europe invested US$ 19, 509 million in 2000, which increased to US$ 39,895 million (est.) in 2018.
Moreover, R&D in cancer pain care is also expected to offer lucrative growth opportunities for players in the global cancer supportive care products market. For instance, in September 2020, EMD Serono presented its oncology portfolio and pipeline in supportive care in multiple cancers at ESMO 2020.
The global cancer supportive care products market was valued at US$ 27,244.1 Mn in 2019 and is forecast to reach a value of US$ 40,884.0 Mn by 2027 at a CAGR of 4.6% between 2020 and 2027.
Figure 2: Global Cancer Supportive Care Products Market Value (US$ Mn), 2016 – 2027
Market Trends/Key Takeaways
Use of targeted AML drugs alongside best supportive care may not be effective in improving quality of life in cancer patents. For instance, in August 2020, Bristol Myers Squibb reported that Idhifa, which bears an FDA nod in relapsed or refractory AML with an IDH2 mutation, failed to demonstrate efficacy in improving survival within that same patient population when used alongside best supportive care in a late-stage study.
Geriatric co-management for cancer patients is effective in cancer supportive care. For instance, according to a retrospective cohort study ‘Association of Geriatric Comanagement and 90-Day Postoperative Mortality Among Patients Aged 75 Years and Older With Cancer published in August 2020, in JAMA Network Open, geriatric co-management was associated with significantly lower 90-day postoperative mortality among older patients with cancer.
Regulations (US) - Cancer Supportive Care
- In the U.S., the FDA’s Oncologic Drugs Advisory Committee (ODAC) advises on each individual drug approval, meeting endpoint claims and labelling requirements
- Approval regulations also are located under accelerated approval conditions for life- threatening conditions under section 21 CFR part 314, subpart H and 21 CFR part 601, subpart E of the U.S. FDCCA
- The U.S. FDA recommends at least two adequate and well-controlled clinical trials for meeting endpoint of a critical drug
- Various endpoints such as Disease-free-survival (DFS), Objective Response Rate (ORR), Time-to-Progression (TTP), Progression free survival, Time to treatment failure should be clearly mentioned during approval process of the drug and should be decided in co-ordication with the FDA
Off-label usage of drugs
- Chemotherapy and other cancer-supportive drugs can be used off-label. It is primarily dependent on the stage of cancer and the disease progression rate
- The best example for off-label drug usage in cancer supportive care is the pain medication through use of tricyclic anti-depressants
- Another drugs used off-label in cancer supportive care is anti-nauseating drug ‘lorezepam’, administered mostly under the tongue (sub-lingual route). This is not a labelled administration route and the dosage and direction is fully dependent on physician
- However, at certain times, lack of well-evidenced information on off-label drug usage leads to higher risk for medication errors, side effects, and unwanted drug reactions
Global Cancer Supportive Care Products Market: Competitive Landscape
Major players operating in the global cancer supportive care products market include, Amgen Inc., Johnson & Johnson Private Ltd., Merck, Novartis AG, Baxter International, Hoffmann-La Roche Ltd., Fagron, Teva Pharmaceutical Industries Ltd., G1 Therapeutics Inc., APR Applied Pharma Research s.a., Acacia Pharma, EMD Serono, and Kyowa Hakko Kirin Co., Ltd.
Global Cancer Supportive Care Products Market: Key Developments
Major players in the market are focused on presenting new portfolio in order to enhance their market share. For instance, in September 2020, Merck announced that more than 30 abstracts will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 from September 19-21. The abstracts span the company's clinical program in oncology across several innovative modalities and mechanisms that have the potential to advance treatment across a range of tumor types including biliary tract, lung and urothelial (bladder) cancers.